Table 2.
Result of the cost-effectiveness analysis.
| CIK cell Immunotherapy | No adjuvant therapy | Incremental | ICER ($/LY or $/QALY) | |
|---|---|---|---|---|
| Based on RCT data | ||||
| Cost | $115,002 | $53,190 | $61,813 | |
| LY | 11.68 | 9.60 | 2.07 | $29,791 |
| QALY | 8.80 | 6.94 | 1.87 | $33,077 |
| Based on RWD | ||||
| Cost | $110,670 | $57,959 | $52,711 | |
| LY | 12.53 | 10.68 | 1.85 | $28,437 |
| QALY | 9.76 | 7.66 | 2.10 | $25,107 |
CIK, cytokine-induced killer cell; LY, life-year; QALY, quality-adjusted life-year; ICER, Incremental cost-effectiveness ratio; RCT, randomized controlled trial; RWD, real-world data.